Zim Laboratories Ltd.

ZIMLAB

₹109.45

-3.1% (-3.5)

Market Cap

₹550 Cr.

P/E

30.71

About

Zim Laboratories Ltd has established itself as one of the preferred healthcare solution providers in the field of New Drug Delivery Systems (NDDS). The company has pioneered several innovative techn… Read more

Zim Laboratories Ltd has established itself as one of the preferred healthcare solution provi… Read more

Low

52W Range

High

131

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Custom financial statement

Edit rows

Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

9 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Customer Segment

Capex

Asset Break-Up

Operational Metrics

R&D as a % of Total Sales (%)
Source

Peer Comparison

Customers

Gufic Biosciences Ltd.
RPG Life Sciences Ltd.
Sun Pharmaceutical Industries Ltd.
Alkem Laboratories Ltd.
Mankind Pharma

FAQs on Zim Laboratories Ltd. Business

What does Zim Laboratories do?

Zim Laboratories Ltd is a leading healthcare solution provider specializing in New Drug Delivery Systems. They have developed innovative technologies and products in areas such as Pellets, Multiplets, Resinates, Herbals, and Diagnostics.

Who are the competitors of Zim Laboratories?

Zim Laboratories major competitors are Lyka Labs, Kilitch Drugs(India), Medicamen Biotech, Gennex Lab, Jenburkt Pharma, Ambalal Sarabhai Ent, Balaxi Pharma..
Market Cap of Zim Laboratories is ₹550 Crs.
While the median market cap of its peers are ₹588 Crs.

Is Zim Laboratories financially stable compared to its competitors?

Zim Laboratories seems to be less financially stable compared to its competitors.
Altman Z score of Zim Laboratories is 3.34 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Jun Mar Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun Sep		Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec